Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Pfizer pledges $100M to new Antimicrobial Resistance Action Fund » 15:23
07/09/20
07/09
15:23
07/09/20
15:23
PFE

Pfizer

$33.57 /

-0.19 (-0.56%)

, AMGN

Amgen

$252.34 /

+0.74 (+0.29%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, LLY

Eli Lilly

$166.59 /

-2.52 (-1.49%)

, GSK

GlaxoSmithKline

$40.37 /

-0.35 (-0.86%)

, MRK

Merck

$76.99 /

-0.88 (-1.13%)

, MKGAY

Merck KGaA

$0.00 /

+ (+0.00%)

, TEVA

Teva

$11.60 /

+0.21 (+1.84%)

, TAK

Takeda Pharmaceutical

$17.36 /

-0.135 (-0.77%)

, NVO

Novo Nordisk

$65.63 /

-0.23 (-0.35%)

, JNJ

Johnson & Johnson

$143.03 /

-0.21 (-0.15%)

, NVS

Novartis

$87.53 /

-0.585 (-0.66%)

Pfizer (PFE) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$33.57 /

-0.19 (-0.56%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
AMGN Amgen
$252.34 /

+0.74 (+0.29%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

10:13 Today Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
06/29/20 Mizuho
Eli Lilly price target raised to $164 from $155 at Mizuho
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
MRK Merck
$76.99 /

-0.88 (-1.13%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

05/15/20 Nord/LB
Merck KGaA downgraded to Hold from Buy at Nord/LB
03/06/20 UBS
UBS backs Neutral on Merck KGaA after Q4 results
12/02/19 Goldman Sachs
Merck KGaA reinstated with a Sell at Goldman Sachs
10/04/19 Loop Capital
Entegris price target raised to $51 from $47 at Loop Capital
TEVA Teva
$11.60 /

+0.21 (+1.84%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.53 /

-0.585 (-0.66%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.57 /

-0.19 (-0.56%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

MKGAY Merck KGaA
$0.00 /

+ (+0.00%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

NVO Novo Nordisk
$65.63 /

-0.23 (-0.35%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

PFE Pfizer
$33.57 /

-0.19 (-0.56%)

AMGN Amgen
$252.34 /

+0.74 (+0.29%)

LLY Eli Lilly
$166.59 /

-2.52 (-1.49%)

GSK GlaxoSmithKline
$40.37 /

-0.35 (-0.86%)

MRK Merck
$76.99 /

-0.88 (-1.13%)

TEVA Teva
$11.60 /

+0.21 (+1.84%)

TAK Takeda Pharmaceutical
$17.36 /

-0.135 (-0.77%)

JNJ Johnson & Johnson
$143.03 /

-0.21 (-0.15%)

NVS Novartis
$87.53 /

-0.585 (-0.66%)

Conference/Events
Oxford Global Marketing to hold a virtual event » 04:55
07/09/20
07/09
04:55
07/09/20
04:55
ABBV

AbbVie

$99.28 /

-0.06 (-0.06%)

, AZN

AstraZeneca

$54.19 /

+0.7 (+1.31%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$59.58 /

-0.72 (-1.19%)

, GSK

GlaxoSmithKline

$40.72 /

+0.34 (+0.84%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, JAZZ

Jazz Pharmaceuticals

$107.54 /

-1.18 (-1.09%)

, JNJ

Johnson & Johnson

$143.24 /

+0.43 (+0.30%)

, NVS

Novartis

$88.12 /

+0.345 (+0.39%)

, PFE

Pfizer

$33.76 /

-0.27 (-0.79%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RTRX

Retrophin

$20.86 /

-0.04 (-0.19%)

, SNY

Sanofi

$51.54 /

+0.14 (+0.27%)

, TAK

Takeda Pharmaceutical

$17.49 /

+0.01 (+0.06%)

, TEVA

Teva

$11.39 /

+0.17 (+1.52%)

Formulation &…

Formulation & Delivery Series Biomanufacturing Virtual Congress will be held on July 8-9. Webcast Link

ShowHide Related Items >><<
TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/08/20 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

06/23/20 Barclays
Jazz Pharmaceuticals price target raised to $195 from $183 at Barclays
06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$88.12 /

+0.345 (+0.39%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.76 /

-0.27 (-0.79%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
SNY Sanofi
$51.54 /

+0.14 (+0.27%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TEVA Teva
$11.39 /

+0.17 (+1.52%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TEVA Teva
$11.39 /

+0.17 (+1.52%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RTRX Retrophin
$20.86 /

-0.04 (-0.19%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

  • 09
    Jun
TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

TEVA Teva
$11.39 /

+0.17 (+1.52%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

JAZZ Jazz Pharmaceuticals
$107.54 /

-1.18 (-1.09%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

TEVA Teva
$11.39 /

+0.17 (+1.52%)

TAK Takeda Pharmaceutical
$17.49 /

+0.01 (+0.06%)

SNY Sanofi
$51.54 /

+0.14 (+0.27%)

PFE Pfizer
$33.76 /

-0.27 (-0.79%)

NVS Novartis
$88.12 /

+0.345 (+0.39%)

JNJ Johnson & Johnson
$143.24 /

+0.43 (+0.30%)

GSK GlaxoSmithKline
$40.72 /

+0.34 (+0.84%)

BMY Bristol-Myers
$59.58 /

-0.72 (-1.19%)

AZN AstraZeneca
$54.19 /

+0.7 (+1.31%)

ABBV AbbVie
$99.28 /

-0.06 (-0.06%)

Yesterday
Conference/Events
Oxford Global Marketing to hold a virtual event » 09:24
07/08/20
07/08
09:24
07/08/20
09:24
ABBV

AbbVie

$99.34 /

+0.31 (+0.31%)

, AZN

AstraZeneca

$53.49 /

-0.61 (-1.13%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$60.30 /

+0.09 (+0.15%)

, GSK

GlaxoSmithKline

$40.38 /

-0.625 (-1.52%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, JAZZ

Jazz Pharmaceuticals

$108.72 /

-2.48 (-2.23%)

, JNJ

Johnson & Johnson

$142.81 /

-0.18 (-0.13%)

, NVS

Novartis

$87.77 /

-0.65 (-0.74%)

, PFE

Pfizer

$34.03 /

-0.48 (-1.39%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, RTRX

Retrophin

$20.90 /

+0.34 (+1.65%)

, SNY

Sanofi

$51.40 /

-0.78 (-1.49%)

, TAK

Takeda Pharmaceutical

$17.48 /

-0.18 (-1.02%)

, TEVA

Teva

$11.22 /

-0.31 (-2.69%)

Formulation &…

Formulation & Delivery Series Biomanufacturing Virtual Congress will be held on July 8-9. Webcast Link

ShowHide Related Items >><<
TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

07/07/20 SunTrust
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/10/20 Cowen
AstraZeneca price target raised to $60 from $55 at Cowen
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
BAYRY Bayer
$0.00 /

+ (+0.00%)

06/26/20 JPMorgan
Bayer price target raised to EUR 77 from EUR 75 at JPMorgan
06/26/20 Deutsche Bank
Bayer price target raised to EUR 87 from EUR 85 at Deutsche Bank
06/25/20 Morgan Stanley
Bayer price target raised to EUR 88 from EUR 83 at Morgan Stanley
06/25/20 HSBC
HSBC upgrades Bayer to Buy after settlement on most Monsanto cases in U.S.
BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

06/22/20 Morgan Stanley
Morgan Stanley sees Eliquis patent being upheld, ruling being 'imminent'
06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
06/16/20 Roth Capital
Ideaya Biosciences price target raised to $23 from $12 at Roth Capital
05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/08/20 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
06/01/20 Barclays
Ipsen price target raised to EUR 72 from EUR 62 at Barclays
06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

06/23/20 Barclays
Jazz Pharmaceuticals price target raised to $195 from $183 at Barclays
06/01/20 SVB Leerink
Jazz Pharmaceuticals price target raised to $169 from $160 at SVB Leerink
05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/01/20 JMP Securities
Minerva's seltorexant still 'underappreciated' upside driver, says JMP
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
NVS Novartis
$87.77 /

-0.65 (-0.74%)

07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$34.03 /

-0.48 (-1.39%)

07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
07/02/20 BMO Capital
Moderna mRNA platform supported by Pfizer vaccine data, says BMO Capital
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

06/16/20 BTIG
Retrophin initiated with a Buy at BTIG
02/25/20 Barclays
Retrophin downgraded to Equal Weight from Overweight at Barclays
01/13/20 JMP Securities
JMP says continues to like Retrophin opportunity
08/23/19 BMO Capital
Retrophin price target lowered to $33 from $38 at BMO Capital
SNY Sanofi
$51.40 /

-0.78 (-1.49%)

07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
06/24/20 Roth Capital
Translate Bio price target raised to $30 from $25 at Roth Capital
TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
TEVA Teva
$11.22 /

-0.31 (-2.69%)

07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 William Blair
Pfenex partner CHMP opinion 'material de-risking event,' says William Blair
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
TEVA Teva
$11.22 /

-0.31 (-2.69%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RTRX Retrophin
$20.90 /

+0.34 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

  • 09
    Jun
TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

TEVA Teva
$11.22 /

-0.31 (-2.69%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

JAZZ Jazz Pharmaceuticals
$108.72 /

-2.48 (-2.23%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

TEVA Teva
$11.22 /

-0.31 (-2.69%)

TAK Takeda Pharmaceutical
$17.48 /

-0.18 (-1.02%)

SNY Sanofi
$51.40 /

-0.78 (-1.49%)

PFE Pfizer
$34.03 /

-0.48 (-1.39%)

NVS Novartis
$87.77 /

-0.65 (-0.74%)

JNJ Johnson & Johnson
$142.81 /

-0.18 (-0.13%)

GSK GlaxoSmithKline
$40.38 /

-0.625 (-1.52%)

BMY Bristol-Myers
$60.30 /

+0.09 (+0.15%)

AZN AstraZeneca
$53.49 /

-0.61 (-1.13%)

ABBV AbbVie
$99.34 /

+0.31 (+0.31%)

Monday
Periodicals
Roche's Genentech loses appeals court bid over Amgen Mvasi, Bloomberg reports » 10:46
07/06/20
07/06
10:46
07/06/20
10:46
RHHBY

Roche

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$262.61 /

+4.21 (+1.63%)

Roche's (RHHBY)…

Roche's (RHHBY) Genentech unit lost its appeals court bid to halt Amgen's (AMGN) biosimilar of the cancer drug Avastin, according to Bloomberg Law. Genentech had argued that Amgen didn't provide adequate notice, as required by law, before it began selling the biosimilar Mvasi. The U.S. Court of Appeals for the Federal Circuit ruled Monday that adequate notice had been given, the report notes. Reference Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$262.61 /

+4.21 (+1.63%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
AMGN Amgen
$262.61 /

+4.21 (+1.63%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$262.61 /

+4.21 (+1.63%)

RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$262.61 /

+4.21 (+1.63%)

RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$262.61 /

+4.21 (+1.63%)

AMGN Amgen
$262.61 /

+4.21 (+1.63%)

Periodicals
Roche unit loses bid to halt sales of Amgen's Avastin biosimilar, Bloomberg says » 09:24
07/06/20
07/06
09:24
07/06/20
09:24
AMGN

Amgen

$258.40 /

+3.24 (+1.27%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Roche's (RHHBY)…

Roche's (RHHBY) Genentech unit lost an appeal ruling over Amgen's (AMGN) MVASI, according to Bloomberg.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

07/03/20 AlphaValue
Roche upgraded to Add from Reduce at AlphaValue
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

RHHBY Roche
$0.00 /

+ (+0.00%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

AMGN Amgen
$258.40 /

+3.24 (+1.27%)

Friday
Upgrade
Roche upgraded to Add from Reduce at AlphaValue » 12:55
07/03/20
07/03
12:55
07/03/20
12:55
RHHBY

Roche

$0.00 /

+ (+0.00%)

AlphaValue upgraded Roche…

AlphaValue upgraded Roche to Add from Reduce.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Over a week ago
Recommendations
Halozyme price target raised to $31 from $28 at Piper Sandler » 05:02
07/02/20
07/02
05:02
07/02/20
05:02
HALO

Halozyme

$27.39 /

+0.59 (+2.20%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Halozyme to $31 from $28 and keeps an Overweight rating on the shares after speaking with a key opinion leader from a large academic center to gauge where Darzalex Faspro was in the adoption cycle. Through an accelerated process due to COVID, Darzalex Faspro has been approved for usage in the outpatient setting at this center beginning next week, Catanzaro tells investors in a research note. The analyst does not expect, consistent with Halozyme guidance, meaningful royalties in Q2. However, Catanzaro believes Q3 could see realization of IV to subQ conversion based on the KOL's feedback that the majority of patients could be easily converted.

ShowHide Related Items >><<
HALO Halozyme
$27.39 /

+0.59 (+2.20%)

HALO Halozyme
$27.39 /

+0.59 (+2.20%)

07/01/20 Benchmark
Benchmark starts Halozyme at Buy with $39 price target
07/01/20 Benchmark
Halozyme initiated with a Buy at Benchmark
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
HALO Halozyme
$27.39 /

+0.59 (+2.20%)

HALO Halozyme
$27.39 /

+0.59 (+2.20%)

Initiation
Benchmark starts Halozyme at Buy with $39 price target » 06:35
07/01/20
07/01
06:35
07/01/20
06:35
HALO

Halozyme

$26.80 /

+0.98 (+3.80%)

As previously reported,…

As previously reported, Benchmark analyst Robert Wasserman initiated coverage of Halozyme (HALO) with a Buy rating and $39 price target. The company's Enhanze drug delivery technology, which is intended to reduce the treatment burden to patients and healthcare systems, has been licensed to leading drugmakers that include Roche (RHHBY), Pfizer (PFE), Janssen (JNJ), AbbVie (ABBV), Eli Lilly (LLY), Bristol-Myers Squibb (BMY), and others, Wasserman noted.

ShowHide Related Items >><<
HALO Halozyme
$26.80 /

+0.98 (+3.80%)

HALO Halozyme
$26.80 /

+0.98 (+3.80%)

07/01/20 Benchmark
Halozyme initiated with a Buy at Benchmark
06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
HALO Halozyme
$26.80 /

+0.98 (+3.80%)

HALO Halozyme
$26.80 /

+0.98 (+3.80%)

Initiation
Halozyme initiated with a Buy at Benchmark » 06:13
07/01/20
07/01
06:13
07/01/20
06:13
HALO

Halozyme

$26.80 /

+0.98 (+3.80%)

Benchmark analyst Robert…

Benchmark analyst Robert Wasserman initiated coverage of Halozyme with a Buy rating and $39 price target.

ShowHide Related Items >><<
HALO Halozyme
$26.80 /

+0.98 (+3.80%)

HALO Halozyme
$26.80 /

+0.98 (+3.80%)

06/29/20 Piper Sandler
Herceptin/Perjecta approval another win for Halozyme, says Piper
05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
HALO Halozyme
$26.80 /

+0.98 (+3.80%)

HALO Halozyme
$26.80 /

+0.98 (+3.80%)

Recommendations
Herceptin/Perjecta approval another win for Halozyme, says Piper » 14:57
06/29/20
06/29
14:57
06/29/20
14:57
HALO

Halozyme

$25.70 /

+0.91 (+3.67%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $28 price target on Halozyme Therapeutics (HALO) after Halozyme partner Roche (RHHBY) received approval for the subQ FDC of Herceptin/Perjeta using Halozyme's ENHANZE technology. Catanzaro noted that the approval comes "well ahead" of the October 18 PDUFA data and comes with a broad label that covers both early-stage and metastatic disease. Catanzaro said that, overall, he thinks that Phesgo could be an underappreciated blockbuster product which he expects will drive another inflection in royalties for Halozyme on top of the recently approved Darzalex Faspro.

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

HALO Halozyme
$25.70 /

+0.91 (+3.67%)

HALO Halozyme
$25.70 /

+0.91 (+3.67%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
RHHBY Roche
$0.00 /

+ (+0.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
RHHBY Roche
$0.00 /

+ (+0.00%)

HALO Halozyme
$25.70 /

+0.91 (+3.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

HALO Halozyme
$25.70 /

+0.91 (+3.67%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.